Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Stakeholder Perspectives on Engaging With Cerebral Palsy Research Studies After Onset of COVID-19 in the United States

Divya Joshi, a,b Nayo Hill, PT, DPT, PhD, a,b Alexandra Hruby, a,b Shreya Viswanathan, a,c Carson Ingo, PhD, a,d Heidi Roth, PT, DHS, a,e Theresa Sukal-Moulton, PT, DPT, PhD a,f

From the aDepartment of Physical Therapy & Human Movement Sciences, Feinberg School of Medicine, Northwestern University, Chicago, IL; bDepartment of Biomedical Engineering, Northwestern University, Evanston, IL; cDepartment of Bioengineering, University of Pennsylvania, Philadelphia, PA; dDepartment of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL; eShirley Ryan AbilityLab, Chicago, IL; and fDepartment of Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, IL.

Abstract

Objective: To investigate the effect of the coronavirus disease 2019 (COVID-19) pandemic on perspectives toward participation in cerebral palsy (CP) research.

Design: An online survey with questions relating to the comfort levels of research participation was filled out by people who had CP or had a child with CP.

Setting: The online survey was administered through Research Electronic Data Capture platform.

Participants: A total of 233 (n=233) individuals with CP (42.5%; n=99) or with a child with CP (57.1%; n=133) consented and at least partially completed the online survey (n=210 complete; n=23 partially complete). All participants resided in the United States.

Interventions: Not applicable.

Main Outcome Measures: Readiness to participate was analyzed in the context of the time point for research participation during COVID-19 and whether or not the study offered direct benefits to participants.

Results: Participants were consistently willing to participate sooner in studies that offered direct benefit than in those that did not. Adults responding for themselves had sooner time points for studies without direct benefit compared with parents answering for a child (P=0.030). Gross Motor Function Classification System level, but not age or CP type, affected the time point for studies without direct benefit (P=0.017). Personal values influenced selected time point for studies without direct benefit (P=0.007), whereas environmental factors affected the time point for studies with direct benefit (P=0.002). Local COVID-19 incidence rates were not associated with time points for either research type; however, respondents expected precautions to be taken if they chose to participate.

Conclusions: As the pandemic evolves, researchers should consider the perspectives of potential participants as well as ethical and safety factors when reinitiating in-person CP research.

Archives of Physical Medicine and Rehabilitation 2021;102:1547–55
© 2021 by the American Congress of Rehabilitation Medicine

Research studies are the primary mechanism by which clinicians and scientists improve understanding of pathophysiology and treatment options for cerebral palsy (CP), a group of movement disorders caused by injury or disruption to the developing brain. An estimated 60%-80% of rehabilitation studies in the United States do not meet their expected sample size, and studies that focus on pediatric populations, including CP, are prone to difficulties in recruiting the number of participants required for scientific validity.

The coronavirus disease 2019 (COVID-19) global pandemic has resulted in widespread stay-at-home orders and social distancing, which has affected the ability to carry out in-person research studies. Some regions began to reopen businesses and schools by summer of 2020, but there is not consensus on how to ethically...
and safely reinitiate human research. Scientists must consider visit-related factors, policy-related factors, research facility preparedness, and research participant perspectives in evaluating the overall risk of resuming human research. The current study investigates the personal and environmental factors that influence comfort levels of participant stakeholders for participating in CP research during the COVID-19 pandemic.

Methods
An online survey was developed by the study team with review by 6 stakeholders who had CP or a child with CP. The survey was available online between May 6 and July 7, 2020 and disseminated through the Research Electronic Data Capture platform. Informed consent was collected from all participants. The survey consisted of up to 60 questions, with 14 specifically related to comfort with in-person research study participation during the COVID-19 pandemic (supplemental fig S1, available online only at http://www.archives-pmr.org/). This study was approved by Northwestern University’s Institutional Review Board.

Recruitment
Participants had to reside in the United States and be either (1) a parent or legal guardian of a minor with CP or (2) an adult with CP. Participants were recruited directly via email if they had previously participated in pediatric studies at Northwestern University or consented to be contacted through the web-based recruitment tool ResearchMatch.org. Eligible members of the Cerebral Palsy Research Registry were sent a recruitment notification, and clinical partners were encouraged to share the study with eligible patients. Finally, social media sites (Facebook, Twitter, Instagram) were used to share the survey link.

Data analysis
All statistical analyses were conducted using SPSS software with \( P<.05 \) considered statistically significant. Descriptive analysis was completed for age, sex, ethnicity, race, CP diagnosis, and Gross Motor Function Classification System (GMFCS) level. Survey data were analyzed to address the following research questions:

Q1: How soon are potential participants willing to participate in research?
Participants were asked to identify the earliest milestone at which they would be comfortable joining a research study. They were asked to separately answer for studies with potential for direct benefit (ie, clinical trials of interventional physical and occupational therapy studies, drug and treatment efficacy, intensive training) and with no direct benefit (ie, studies aiming to understand basic scientific and biomechanical background of CP). The milestones presented to respondents included: (1) now; (2) after lifting of local stay-at-home orders; (3) after widespread testing for COVID-19; (4) after availability of COVID-19 vaccination; and (5) not in the foreseeable future. Because milestones are ordered chronologically, time point for research participation was coded for analysis with earliest selected time point for a given activity, with the assumption that the respondent would also be willing to participate for the later time points. Analysis focused on time points for studies that have potential direct benefit and studies that have no direct benefit.

Q2: How does participating in research activities compare with other activities?
Participants were asked the earliest milestone (as in Q1) they would engage in the following activities: (1) personal care appointments; (2) social or recreational activities; (3) routine medical appointments; and (4) medical appointments for a new concern. Chi-square tests were performed to analyze whether there was association between the time point for research participation for studies that have potential direct benefit, the time point for research participation for studies that have no direct benefit, and the time points they were comfortable participating in nonresearch activities. Spearman correlations were observed to determine the strengths of association.

Q3: Are demographic characteristics of the potential participant associated with time point for research participation?
We performed separate Kruskal-Wallis tests with time point for research participation for studies that have potential direct benefit and time point for research participation for studies that have no direct benefit as dependent variables and age, GMFCS level, or CP diagnosis as independent variables. For significant main effects, pairwise comparisons were performed with Bonferroni correction for multiple tests.

Q4: Which personal values are associated with time point for research participation?
Personal values included self-rated value placed on CP research overall and participation in CP research. Linear regression was performed with each of these values as predictors and with time point for research participation for studies that have potential direct benefit and time point for research participation for studies that have no direct benefit as the outputs.

Q5: How are environmental factors, including the overall COVID-19 risk, associated with choices about engaging in research activities?
The risk of COVID-19 was represented by the incidence rate (cases per 100,000 persons) for each respondent’s state on the date of survey completion, which was obtained from the COVID-19 Data Repository by the Center for Systems Science and Engineering at Johns Hopkins University. This COVID-19 risk metric, along with preferred location of research participation (regardless of COVID-19 consideration) and transportation typically used for medical appointments, was used in linear regression models to determine whether environmental factors could predict when individuals were willing to participate in in-person research studies (time point for research participation for studies that have potential direct benefit and time point for research participation for studies that have no direct benefit).

List of abbreviations:
COVID-19 coronavirus disease 2019
CP cerebral palsy
GMFCS Gross Motor Function Classification System
Q6: What are common responses about participant decision making during COVID-19?
Open-ended questions about the effect of COVID-19 on research participation decisions were categorized first by whether it had an effect (yes, no, unsure) and further organized by stated reason(s) for response.

Results

Participants
In total, 241 individuals consented and 233 submitted complete (n=210) or partially complete (n=23) surveys. The final sample represents a 10.3% response rate of those directly contacted via email, ResearchMatch.org, and the Cerebral Palsy Research Registry (n=2266). Study sample characteristics are shown in Table 1.11-14 Compared with the United States 2010 Census data, the sample is broadly representative of the national population in terms of sex, ethnicity, and racial composition. Notably, the sample included more respondents who were parents of children with CP (57.1%; n=133) than adults with CP (42.5%; n=99), as opposed to the national population, which consists of 24% minors and 76% adults.15 When results are similar among the caregivers of a child and adults with CP, the term respondent is used to generalize to both; when the results or trends are different, caregiver and adult responses are reported independently.

Participants came from 33 states, as illustrated in supplemental fig S2 (available online only at http://www.archives-pmr.org/). Over half the respondents reside in Illinois (54.5%; n=127). The next 3 most represented states were Indiana (4.72%; n=11), California (3.86%; n=9), and New York (3.43%; n=8). The incidence rates of COVID-19 across the country for the dates of the survey are represented in maps shown in supplemental fig S2 (available online only at http://www.archives-pmr.org/). The total incidence rate in the United States increased from 18,110 to 41,637 cases per 100,000 persons over the duration of the survey.

Time points for research participation (Q1)
As shown in figure 1, more respondents indicated willingness to participate in direct benefit studies compared with no direct benefit at each of the time points. Over a fifth (23.1%; n=49) of the respondents indicated time point for research participation at survey completion (“now”) in a no direct benefit study, whereas 39.4% (n=84) would participate “now” in a direct benefit study. For both study types, the percentage of respondents willing to participate has the steepest rise between “now” and the “lifting of local stay-at-home orders.” A direct benefit study has the smallest change between “widespread testing” and “availability of a vaccination” (11.2%; n=24), whereas a no direct benefit study has the smallest change between “lifting of stay-at-home orders” and “widespread testing” (20.3%; n=43). Frequencies of responses for each time point for research participation can be found in supplemental table S3 (available online only at http://www.archives-pmr.org/).

Perceptions of research studies compared with other appointments (Q2)
As shown in figure 1, at the time of survey completion, the majority of respondents were comfortable going to a medical appointment for a new concern (61%; n=130), but few were willing to participate in a social or recreational activity (9%; n=19). Significant associations were found for all combinations tested (P<.001). Research studies with direct benefit were most closely associated with a routine medical appointment (r=0.564, P<.001), whereas no direct benefit studies had the highest correlation with a social or recreational activity (r=0.600, P<.001). Both types of research studies were least correlated with a medical appointment for a new concern (direct

Table 1  Characteristics of study sample

| Characteristics | Survey Sample | Population (%)11-14 |
|-----------------|---------------|-------------------|
| Total no. of respondents | 233 | 100 |
| Age group (y) | | |
| 0-1 | 2 | 0.9 |
| 2-3 | 10 | 4.3 |
| 4-5 | 14 | 6.0 |
| 6-11 | 53 | 22.7 |
| 12-17 | 54 | 23.2 |
| Total: <18 | 133 | 57.1 |
| 18-30 | 45 | 19.3 |
| 31-50 | 36 | 15.5 |
| 51+ | 18 | 7.7 |
| Total: >18 | 99 | 42.5 |
| Unknown/not reported | 1 | 0.4 |
| Sex assigned at birth | | |
| Female | 120 | 51.5 |
| Male | 112 | 48.1 |
| Unknown/not reported | 1 | 0.4 |
| Ethnicity | | |
| Hispanic or Latino | 23 | 9.9 |
| Not Hispanic or Latino | 204 | 87.6 |
| Unknown/not reported | 6 | 2.6 |
| Race | | |
| American Indian or Alaska Native | 2 | 0.9 |
| Asian | 9 | 3.9 |
| Black or African American | 24 | 10.3 |
| Native Hawaiian or Other Pacific Islander | 1 | 0.4 |
| White | 175 | 75.1 |
| ≥2 Races | 6 | 2.6 |
| Unknown/not reported | 16 | 6.8 |
| GMFCS | | |
| Level I | 60 | 25.8 |
| Level II | 65 | 27.9 |
| Level III | 33 | 14.2 |
| Level IV | 37 | 15.9 |
| Level V | 35 | 15.0 |
| Unknown/not reported | 3 | 1.3 |
| CP diagnosis | | |
| Hemiplegia | 72 | 30.9 |
| Diplegia | 60 | 25.8 |
| Quadriplegia | 76 | 32.6 |
| Other | 19 | 8.2 |
| Unknown/not reported | 6 | 2.6 |

NOTE. Survey percentages are compared with national census and previously published reports on distribution of CP. National census and CP population percentages from references.11-14
Across all age groups, time point for research participation was on average sooner for direct benefit than no direct benefit (see fig 2C). On average, individuals and caregivers of children in GMFCS Level IV and Level V were the least willing to participate across all time points for research participation milestones. Although there were no significant differences between GMFCS levels in time point for research participation for studies that have potential direct benefit ($H(4)=3.917, P=.417$), there were significant differences with time point for research participation for studies that have no direct benefit ($H(4)=12.008, P=.017$). Specifically, there were significant differences in the time point for research participation for studies that have no direct benefit between Level III and Level IV ($t=-45.172, P=.024$) and between Level III and Level V ($t=-45.486, P=.035$). To account for the uneven sample sizes across the GMFCS levels and confirm the significant differences identified by the initial analysis, a post hoc Monte Carlo simulation was run with 100 iterations, with 30 participants with Level I and Level II randomly chosen for inclusion in analysis with Levels III, IV, and V. Across the 100 iterations, there was no significant relationship between GMFCS level and time point for research participation for studies that have potential benefit: $\rho=0.484, P<.001$; no direct benefit: $\rho=0.384, P<.001$ (table 2).

### Time point for research participation relationship to demographics (Q3)

Whether the survey respondent was answering for themselves (as an adult with CP) or for their child did not affect the time point for research participation for studies that have potential direct benefit ($H[1]=0.008, P=.930$) but did significantly affect the time point for research participation for studies that have no direct benefit ($H[1]=4.708, P=.030$), where adults with CP had an earlier time point for research participation for studies that have no direct benefit than parent respondents (fig 2A). At time of survey completion, more adults (31.9%; n=30) than parents (16.2%; n=19) responded “now,” representing the greatest difference between groups. Group differences reduced chronologically, with almost the same percentages willing to participate “after the availability of vaccination” (adults: 92.6%, n=87; parents: 92.3%, n=108) for no direct benefit studies.

Across all age groups, time point for research participation was on average sooner for direct benefit than no direct benefit (see fig 2B). Adults with CP in the 31- to 50-year age group reported the earliest time point for research participation; caregivers of children 2-3 years old reported the earliest time point for research participation.
direct benefit, but there remained a significant relationship between GMFCS level and time point for research participation for studies that have no direct benefit. Furthermore, of the iterations showing significant groupwise differences in time point for research participation for studies that have no direct benefit, 4% showed differences between Level II and Level III (average $t=16.625$, average $P=0.0335$), 100% showed differences between Level III and Level IV (average $t=29.0386$, average $P=0.0259$), and 96% showed differences between Level III and Level V (average $t=28.8884$, average $P=0.0355$).

No significant differences were found between the CP types in time point for research participation for studies that have potential direct benefit ($H[3]=1.186$, $P=0.756$) nor time point for research participation for studies that have no direct benefit ($H[3]=4.579$, $P=0.205$). On average, there are more adults or caregivers of children with hemiplegia and diplegia willing to participate at sooner time points than those with quadriplegia, whereas the respondents who reported “Other” for CP diagnosis were the least willing to participate (see fig 2D).

**Personal predictors of time point for research participation (Q4)**

The mean for self-rated value placed on CP research (of 100) was $94.3\pm9.05$, and value placed on their own participation in CP research was $88.6\pm16.6$. The regression model for time point for research participation for studies that have no direct benefit was significant (table 3) where both value of research and value of participation in research were significant predictors. The time point for research participation for studies that have no direct benefit

---

**Fig 2** Cumulative number of respondents willing to participate in research studies that offer direct benefit (left) and studies that do not offer direct benefit (right), separated by (A) minor or adult status of respondent, (B) age group, (C) GMFCS level, and (D) type of CP diagnosis. *Significance at $P<0.05$. 

---

www.archives-pmr.org
was later as value placed on research increased \((P=.037)\) and sooner as value placed on participation increased \((P=.002)\). The model for time point for research participation for studies that have potential direct benefit was not significant (see table 3).

**Environmental predictors of time point for research participation (Q5)**

Prior to COVID-19, 69.5% \((n=162)\) of respondents would have participated in research in a research laboratory, and 43.3% \((n=101)\) of respondents would have participated in a school. These 2 locations were significant predictors \((research\ laboratory: \(P=.001\); school: \(P=.022\)) for a sooner time point in the time point for research participation for studies that have potential direct benefit regression model with research location (see table 3). The regression model for time point for research participation for studies that have no direct benefit was not significant (see table 3).

**Qualitative responses to the effect of COVID-19 on research participation (Q6)**

A total of 72% of survey participants \((n=169)\) answered whether COVID-19 affected their feelings on research participation. Participant responses reflected a range in whether COVID-19 affected feelings on research participation, and many provided additional reasons for their perceptions (fig 3). The most common reasons included if proper precautions were taken, travel distance to and location of the study site, or if the participant or a family member was immunocompromised. Selected quotes can be found in supplemental table S4 (available online only at http://www.archives-pmr.org/).

**Discussion**

This study explored the comfort level of participating in research by individuals with CP during the COVID-19 pandemic by analyzing willingness to participate in 2 key categories of in-person research studies: studies that offer potential direct benefit and studies that do not offer direct benefit. The findings revealed a number of important considerations for researchers as they plan research during COVID-19.

The majority of respondents were willing to attend either an acute or routine medical appointment in the near future, but few were comfortable with casual, nonessential outings, such as personal care or social activities, potentially because of immunocompromised family members or anxiety about the pandemic.

### Table 3  Linear regression parameters of the effect of personal predictors and environmental predictors on the readiness to return to research studies with and without direct benefit

| Personal Predictors | Research Study With Direct Benefit | Research Study Without Direct Benefit |
|---------------------|------------------------------------|---------------------------------------|
|                     | \(F_{2,201}=0.269, P=.764\)        | \(F_{2,200}=5.117, P=.007^*\)        |
| \(\beta\)           | \(P\) Value                        | \(\beta\)                             | \(P\) Value                        |
| Value placed on     |                                    |                                       |                                    |
| Research            | 0.049                              | .558                                 | 0.172                              | .037^*                             |
| Participation       | -0.057                             | .493                                 | -0.259                             | .002^*                             |
| Environmental Predictors |                                    |                                       |                                    |
|                      | \(F_{13,191}=2.692, P=.002^*\)    | \(F_{13,190}=1.453, P=.139\)        |
| \(\beta\)           | \(P\) Value                        | \(\beta\)                             | \(P\) Value                        |
| COVID-19 incidence  | -0.049                             | .486                                 | -0.077                             | .296                               |
| Location            |                                    |                                       |                                    |
| Clinic/hospital, already receiving services | 0.048 | .488                      | 0.033                              | .643                               |
| Clinic/hospital, not already receiving services | -0.111 | .137                     | -0.127                             | .104                               |
| Park/community center | 0.017 | .829                      | 0.031                              | .698                               |
| Research laboratory | -0.267                             | .001^*                               | -0.159                             | .046^*                             |
| School              | -0.178                             | .022^*                               | -0.128                             | .112                               |
| Home                | 0.015                              | .832                                 | -0.031                             | .668                               |
| Other location      | -0.050                             | .463                                 | -0.003                             | .961                               |
| Transportation      |                                    |                                       |                                    |
| Drive self          | 0.137                              | .161                                 | 0.175                              | .087                               |
| Family member drives | 0.070 | .401                      | 0.096                              | .272                               |
| Public transportation | 0.076 | .384                      | 0.036                              | .694                               |
| Car service         | 1.045                              | .297                                 | 0.091                              | .287                               |
| Other transportation | 0.057 | .452                      | 0.053                              | .502                               |

**NOTE.** Whole model output and significance values are reported, as are coefficients and significance of individual predictors; \(\beta\) values refer to the standardized coefficients resulting from the regression.  

* Significance at \(P<.05\).
Research participation is perceived as less urgent than medical needs but as more important than casual outings, with direct benefit studies similar to a routine medical visit and no direct benefit studies similar to a social activity. Although specific dates for these milestones depend on local regulations and will vary by location, these results illustrate a general timeline that can be followed by researchers when preparing for engagement in research.

Although COVID-19 is rapidly evolving, it has been shown that older adults with the illness have higher mortality rates (median age of death >65 years), and individuals of any age with underlying medical conditions are more susceptible to the disease and have worse prognosis. Despite elevated risk, age was not a significant factor in time point for research participation, although a related factor of the person completing the survey (adult with CP or parent/guardian of a minor with CP) was significant. Compared with adults answering for themselves, parents were less comfortable with their children participating. This may be related to the total number of individuals from a family that need to be engaged, a parental drive to be protective, or a fear of their own child being a “guinea pig” for clinical testing.

GMFCS level did have a significant effect on the willingness to participate in a no direct benefit study, and Level IV or Level V groups who are more likely to have severe comorbidities were the most conservative in their approach. In contrast, GMFCS level did not have an effect on time point for research participation for studies that have potential direct benefit, and the type of CP diagnosis did not affect time point for research participation in either type of study. Post hoc Monte-Carlo tests revealed that results were robust to sample size differences.

The more respondents valued their own participation in research, the sooner they were likely to be willing to participate in no direct benefit studies. Conversely, value of research in general (disregarding their own involvement) actually predicted a later time point for research participation. Although these relationships were significant, the notable finding is that although research and participation are highly valued by respondents, risk of COVID-19 exposure may affect personal decision on when to participate.

Environmental factors related to pre-COVID-19 life appeared to have a small influence on an individual’s time point for research participation for studies that have potential direct benefit but not time point for research participation for studies that have no direct benefit. Particularly, selection of a research laboratory or school as a potential study location indicated that respondents would participate sooner in studies that offer direct benefit. This could be related to perceived structure of these 2 locations instilling confidence in the quality of research and may extend to an expectation of precautions and safety measures against COVID-19, although this would require further investigation. Although few respondents (32.6%; n=76) considered outdoor recreational spaces for research participation prior to COVID-19, outside may be a reasonable solution in some study locations during the pandemic for safe in-person participation.

Surprisingly, the local burden of COVID-19, represented by the local COVID-19 incidence rate on the day the respondent took the survey, did not have a significant effect on the time point for research participation for either type of research study. We did not specifically gauge respondents’ knowledge of their community’s burden at the time of the survey. Recent surveys revealed variable understanding of the mode of transmission and symptoms of COVID-19, with considerable inaccurate beliefs regarding origination, transmission, and prevention of COVID-19, including among those with chronic conditions.
misunderstanding of COVID-19 information could skew reac-
tions, there are also local burdens not directly captured by incident
rate or other quantitative values that may influence responses and
may be reflected in open-ended answers.

Study limitations
We used the COVID-19 incidence rates recorded at the state level;
however, finer precision at the county or zip code level may yield
a tighter coupling with local attitudes, especially in metropolitan
areas. Additionally, the majority of participants resided in Illinois
and only 33 states were represented, introducing a potential geo-
graphic bias in the results. Demographically, there is a slight
underrepresentation of minorities (Hispanic/Latino ethnicities and
non-White races) and no data indicating socioeconomic status of
respondents, both of which are factors that are significantly corre-
lated with COVID-19 burden. Finally, respondents were asked
to answer some questions as they would have prior to COVID-19,
which may have been affected by recall bias.

Conclusions
There is limited guidance on how human research, particularly
in pediatric and at-risk populations, should be safely carried out
during COVID-19. The current study provides insight into the
perceptions of individuals with CP or their caregiver when con-
sidering engaging with research. Results from this study could
also serve as the basis for further exploration about how readi-
ness for participation may be improved in collaboration with
potential participants for a specific study. The relatively large
numbers of respondents willing to engage in research during the
COVID-19 pandemic demonstrate the importance of part-
nership for new discovery in CP. It is therefore the responsibil-
ity of investigators to reach out to potential participants or
participant representatives to implement research in a way that
is both respectful of necessary scientific rigor and responsible
to the public health crisis.

Supplier
a SPSS software version 26; SPSS Inc.

Keywords
Cerebral palsy; COVID-19; Pandemics; Rehabilitation

Corresponding author
Theresa Sukal-Moulton, PT, DPT, PhD, Northwestern University,
Department of Physical Therapy & Human Movement Sciences,
Feinberg School of Medicine, 645 N Michigan Ave, Suite 1100,
Chicago, IL 60611. E-mail address: theresa-moulton@northwestern.edu.

Acknowledgments
We thank Kristina Zvolanek, BS, and Vatsala Goyal, MS, for their
help in design of survey questions and recruitment of participants.

References
1. Rosenbaum P, Paneth N, Leviton A, Goldstein M, Bax M. A report:
the definition and classification of cerebral palsy April 2006. Dev Med
Child Neurol 2007;49:8–14.
2. Blanton S, Morris DM, Prettyman MG, et al. Lessons learned in par-
ticipant recruitment and retention: the EXCITE trial. Phys Ther
2006;86:1520–33.
3. Beckers LWM, Rameckers EAA, Smeets RJE, et al. Barriers to
recruitment of children with cerebral palsy in a trial of home-based
training. Contemp Clin Trials Commun 2019;15:100371.
4. Trauth JM, Jewell IK, Ricci E, Musa D, Siminoff L. Public attitudes
regarding willingness to participate in medical research studies. J Heal
Soc Policy 2000;12:23–43.
5. Padala PR, Jendro AM, Padala KP. Conducting clinical research dur-
ing the COVID-19 pandemic: investigator and participant perspec-
tives. JMRI Public Heal Survell 2020;6:e18887.
6. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG.
Research electronic data capture (REDCap)-a metadata-driven meth-
odology and workflow process for providing translational research
informatics support. J Biomed Inform 2009;42:377–81.
7. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: build-
ing an international community of software platform partners. J
Biomed Inform 2019;95:103208.
8. Harris PA, Scott KW, Lebo L, Hassan N, Lightner C, Pulley J.
ResearchMatch: a national registry to recruit volunteers for clinical
research. Acad Med 2012;87:66–73.
9. Hurley DS, Sukal-Moulton T, Msall ME, Gaebler-Spira D, Krosschell
KJ, Dewald JP. The Cerebral Palsy Research Registry: development
and progress toward national collaboration in the United States. J
Child Neurol 2011;26:1534–41.
10. Dong E, Du H, Gardner L. An interactive web-based dashboard
to track COVID-19 in real time. Lancet Infect Dis 2020;20:
533–4.
11. Howden LM, Meyer JA. Age and sex composition: 2010. Available at:
www.census.gov/population. Accessed July 30, 2020.
12. Humes KR, Jones NA, Ramirez RR. Overview of race and Hispanic
origin: 2010 (2010 census briefs). Available at: www.whitehouse.gov/omb.
Accessed July 30, 2020.
13. Reid SM, Carlin JB, Reddihough DS. Using the Gross Motor Function
Classification System to describe patterns of motor severity in cerebral
palsy. Dev Med Child Neurol 2011;53:1007–12.
14. Yeargin-Allsopp M, Braun KVN, Doernberg NS, Benedict RE, Kirby
RS, Durkin MS. Prevalence of cerebral palsy in 8-year-old children in
three areas of the United States in 2002: a multisite collaboration.
Pediatrics 2008;121:547–54.
15. Wortham JM, Lee JT, Althomsons S, et al. Characteristics of persons
who died with COVID-19 — United States, February 12-May 18,
2020. MMWR Morb Mortal Wkly Rep 2020;69:923–9.
16. Sanyalou A, Okorie C, Marinkovic A, et al. Comorbidity and its
impact on patients with COVID-19. SN Compr Clin Med 2020 Jun
25. [Epub ahead of print].
17. Tromp K, van de Vathorst S. Parents’ perspectives on decisions to
participate in pediatric clinical research: results from a focus
group study with laypeople. J Empir Res Hum Res Ethics
2019;14:243–53.
18. Minciu I. Clinical correlations in cerebral palsy. Maedica (Buchar)
2012;7:319–24.
19. Shevell MI, Dagenais L, Hall N; REPACQ Consortium. Comorbid-
ities in cerebral palsy and their relationship to neurologic subtype and
GMFCS level. 2009;72:2090–6.
20. Onany MB, Hassan M. Opinion: here’s how we restore productivity
and vigor to the biomedical research workforce in the midst of
COVID-19. Proc Natl Acad Sci U S A 2020;117:10612–4.
21. Centers for Disease Control and Prevention. Preparing K-12 school
administrators for a safe return to school in fall 2020. Available at:
https://www.cdc.gov/coronavirus/2019-ncov/community/schools-
childcare/prepare-safe-return.html. Accessed August 5, 2020.
22. Freeman S, Eykelbosh A. COVID-19 and outdoor safety: considera-
tions for use of outdoor recreational spaces. Vancouver: National Col-
loborating Centre for Environmental Health. 2020.
23. Ioannidis JPA. Coronavirus disease 2019: the harms of exaggerated
information and non-evidence-based measures. Eur J Clin Invest
2020;50:e13222.
24. Geldsetzer P. Use of rapid online surveys to assess people’s
perceptions during infectious disease outbreaks: a cross-
sectional survey on COVID-19. J Med Internet Res 2020;22:
e18790.
25. Wolf MS, Serper M, Opsasnick L, et al. Awareness, attitudes, and
actions related to COVID-19 among adults with chronic condi-
tions at the onset of the U.S. outbreak. Ann Intern Med
2020;173:100–9.
26. Webb Hooper M, Nápoles AM, Pérez-Stable EJ. COVID-19 and
racial/ethnic disparities. JAMA 2020;323:2466–7.